alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 76, Number 59 (Monday, March 28, 2011)]
[Notices]
[Page 17164]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-6929]


-----------------------------------------------------------------------

OVERSEAS PRIVATE INVESTMENT CORPORATION


Submission of OMB Review; Comments Request

AGENCY: Overseas Private Investment Corporation (OPIC).

ACTION: Request for comments.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Paperwork Reduction Act (44 U.S.C. 
Chapter 35), agencies are required to publish a Notice in the Federal 
Register notifying the public that the Agency has prepared an 
information collection request for OMB review and approval and has 
requested public review and comment on the submission. Comments are 
being solicited on the need for the information; the accuracy of the 
Agency's burden estimate; the quality, practical utility and clarity of 
the information to be collected; and ways to minimize the reporting 
burden, including automated collection techniques and uses of other 
forms of technology. The proposed form under review, OPIC form-168 A & 
B, is summarized below, OMB-3420-0020.

DATES: Comments must be received by May 27, 2011.

ADDRESSES: Copies of the subject form and the request for review 
prepared for submission to OMB may be obtained from the Agency 
Submitting Officer. Comments on the form should be submitted to the 
Agency Submitting Officer.

FOR FURTHER INFORMATION CONTACT: Agency Submitting Officer: Essie 
Bryant, Records Management Officer, Overseas Private Investment 
Corporation, 1100 New York Avenue, NW., Washington, DC 20527; (202) 
336-8563.

SUMMARY OF FORM UNDER REVIEW:
    Type of Request: Revised Form.
    Title: Expedited Screening Questionnaire (ESQ).
    Form Number: OPIC-168 A & B.
    Frequency of Use: OPIC-supported financial intermediaries will 
complete Form 168A and 168B for each company in which they propose to 
invest. Form could be used by any given OPIC-supported financial 
intermediary between 3-4 times per year depending on the number 
investments the financial intermediary intends to consummate in a given 
year.
    Type of Respondents: Business or other for-profit institution.
    Standard Industrial Classification Codes: All.
    Description of Affected Public: U.S. companies or citizens 
investing overseas
    Reporting Hours: 1 hour per project.
    Number of Responses: 63 per year.
    Federal Cost: $1,280.
    Authority for Information Collection: Section 231 and 234(b) and 
(c) of the Foreign Assistance Act of 1961, as amended.
    Abstract (Needs and Uses): Form 168A and 168B is the principal 
document used by OPIC to determine OPIC-supported financial 
intermediaries' compliance with OPIC economic, environmental, labor 
rights, and human rights policies.

    Dated: March 18, 2011.
Nichole Cadiente,
Administrative Counsel, Department of Legal Affairs.
[FR Doc. 2011-6929 Filed 3-25-11; 8:45 am]
BILLING CODE M
§ 245a.19 Interviews. ( a ) All aliens filing applications for adjustment of status with the Service under this section must be personally interviewed, except that the adjudicative interview may be waived for a child under the age of 14, or when it is impractical because of the health or advanced age of the applicant. Applicants will be interviewed by an immigration officer as determined by the Director of the National Benefit Center. An applicant failing to appear for the scheduled interview may, for good cause, be afforded another interview. Where an applicant fails to appear for two scheduled interviews, his or her application shall be denied for lack of prosecution. Applications for LIFE Legalization adjustment may be denied without interview if the applicant is determined to be statutorily ineligible.
( b ) At the time of the interview, wherever possible, original documents must be submitted except the following: official government records; employment or employment-related records maintained by employers, unions, or collective bargaining organizations; medical records; school records maintained by a school or school board; or other records maintained by a party other than the applicant. Copies of records maintained by parties other than the applicant which are submitted in evidence must be certified as true and correct by such parties and must bear their seal or signature or the signature and title of persons authorized to act in their behalf.
( c ) If at the time of the interview the return of original documents is desired by the applicant, they must be accompanied by notarized copies or copies certified true and correct by the alien's representative. At the discretion of the district director, original documents, even if accompanied by certified copies, may be temporarily retained for forensic examination by the Service.
[66 FR 29673, June 1, 2001, as amended at 85 FR 46927, Aug. 3, 2020]
EXHIBIT 23(a)

     INDEPENDENT AUDITORS' CONSENT

     We  consent  to the  incorporation  by  reference  in (i) the  Registration
     Statements No. 2-96961 and No. 33-28095 on Form S-8 and related  Prospectus
     of Heilig-Meyers Company relating to Common Stock issued and issuable under
     the 1983 Stock Option Plan of the Company, (ii) the Registration Statements
     No.  33-35263,  No.  33-50086  and No.  33-64616  on Form  S-8 and  related
     Prospectuses of  Heilig-Meyers  Company relating to Common Stock issued and
     issuable  under  the 1990  Stock  Option  Plan of the  Company,  (iii)  the
     Registration   Statement   No.   33-43791  on  Form  S-8  relating  to  the
     Heilig-Meyers  Company Employee Stock Purchase Plan and related  Prospectus
     of the Company, (iv) Registration Statements No. 33-54261 and No. 333-29105
     on Form S-8 and related  Prospectuses of Heilig-Meyers  Company relating to
     Common Stock  issued and  issuable  under the 1994 Stock Option Plan of the
     Company, and (v) the Registration Statements No. 333-07753,  No. 333-29929,
     No. 333-45129 and No.  333-320825 on Form S-3 and the related  Prospectuses
     of  Heilig-Meyers  Company  of our  report  dated  March  25,  1998  on the
     consolidated financial statements and schedule of Heilig-Meyers Company and
     subsidiaries,  as  listed  under  Items  14(a)  (1) and (2),  appearing  in
     Amendment No. 2 to the Annual Report on Form 10-K of Heilig-Meyers  Company
     and subsidiaries for the year ended February 28, 1998.

     /s/Deloitte & Touche LLP

     Richmond, Virginia
     January 6, 1998


                                       18
<PAGE>
Electronically Filed Intermediate Court of Appeals CAAP-12-0000541 22-APR-2015 09:01 AM
UNITED STATES OF AMERICA

Before the

SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934 

Release No. 83769 / August 3, 2018

ADMINISTRATIVE PROCEEDING 

File No. 3-18527

In the Matter of

DEVERE USA, INC.

Respondent.

:

:

:

:

:

:

:

EXTENSION ORDER

The Division of Enforcement (“Division”) has requested an extension of time until 

February 28, 2019 to submit a Proposed Plan of Distribution under Rule 1101(a) of the 

Commission’s Rules on Fair Fund and Disgorgement Plans, 17 C.F.R. § 201.1101(a).

On June 4, 2018, the Commission issued an Order Instituting Administrative and 

Cease-and-Desist Proceedings, Pursuant to Sections 203(e) and 203(k) of the Investment 

Advisers Act of 1940, Making Findings, and Imposing Remedial Sanctions and a Cease-andDesist Order (“Order”)1

against deVere USA, Inc. (the “Respondent”), an investment adviser. 

In the Order, the Commission found that, between at least June 2013 and March 2016, the 

Respondent failed to make full and fair disclosure to clients and prospective clients of material 

conflicts of interest regarding compensation obtained from third-party product and service 

providers. The Order required the Respondent to pay an $8,000,000.00 civil money penalty to 

the Commission. The Commission also created a Fair Fund, pursuant to Section 308(a) of the 

Sarbanes-Oxley Act of 2002, as amended, so the penalty could be distributed to investors 

harmed by the Respondent’s conduct described in the Order.

 

1

 Adviser Act Rel. No. 4933 (June 4, 2018).
2

In its request for an extension of time, the Division states that it needs time to solicit 

and evaluate fund administrator proposals, develop the distribution methodology, and develop 

the plan of distribution. 

Accordingly, for good cause shown, IT IS HEREBY ORDERED that the Division’s 

request for an extension of time until February 28, 2019 to submit a Proposed Plan of 

Distribution is granted.

For the Commission, by its Secretary, pursuant to delegated authority. 

Brent J. Fields

Secretary
UNITED STATES OF AMERICA

Before the

SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934 

Release No. 89383 / July 23, 2020

ADMINISTRATIVE PROCEEDING 

File No. 3-19793

In the Matter of

Morgan Stanley Smith Barney LLC

Respondent.

:

:

:

:

:

:

:

EXTENSION ORDER

The Division of Enforcement (“Division”) has requested an extension of time until 

April 30, 2021 to submit a Proposed Plan of Distribution under Rule 1101(a) of the 

Commission’s Rules on Fair Fund and Disgorgement Plans, 17 C.F.R. § 201.1101(a).

On May 12, 2020, the Commission issued an Order Instituting Administrative and 

Cease-and-Desist Proceedings, Pursuant to Section 15(b) of the Securities Exchange Act of 

1934 and Sections 203(e) and 203(k) of the Investment Advisers Act of 1940, Making 

Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order (“Order”) against 

Morgan Stanley Smith Barney LLC (“MSSB” or the “Respondent”). The Order required the 

Respondent to pay a $5,000,000.00 civil money penalty to the Commission. The Commission 

also created a Fair Fund, pursuant to Section 308(a) of the Sarbanes-Oxley Act of 2002, so the 

penalty paid could be distributed to investors harmed by the Respondent’s conduct described 

in the Order.

In its request for an extension of time, the Division states that it needs time to receive 

account and trading data from October 2012 until June 2017 from MSSB so that staff can 

evaluate the feasibility of a distribution, and if staff determines that such a distribution is 

feasible, the staff must solicit and evaluate fund administrator proposals and select a fund 
2

administrator to handle the distribution, develop a distribution methodology in conjunction 

with the fund administrator, and then develop the plan of distribution. 

Accordingly, for good cause shown, IT IS HEREBY ORDERED that the Division’s 

request for an extension of time until April 30, 2021 to submit a Proposed Plan of Distribution 

is granted.

For the Commission, by its Secretary, pursuant to delegated authority. 

Vanessa A. Countryman

Secretary
#### § 79.15 Proof of onset of leukemia more than two years after first exposure.

The Program will presume that the date of onset was the date of diagnosis as indicated in the medical documentation accepted by the Program as proof of the claimant's leukemia. The date of onset must be more than two years after the date of first exposure as determined under § 79.14(b).
#### In the Matter of the Claim of Albert Nathanson, Respondent, against Ignaz Strauss & Co., Inc., et al., Appellants. State Industrial Board, Respondent.

All concur.
###### Editorial Note on Part 1246

#### Editorial Note:

Nomenclature changes to part 1246 appear at 68 FR 9846, Feb. 28, 2003, and 68 FR 10359, Mar. 5, 2003.

#### § 1246.7 Appeals.

Pursuant to 8 CFR part 1003, an appeal shall lie from a decision of an immigration judge under this part to the Board of Immigration Appeals. An appeal shall be taken within 30 days after the mailing of a written decision or the stating of an oral decision. The reasons for the appeal shall be specifically identified in the Notice of Appeal (Form EOIR 26); failure to do so may constitute a ground for dismissal of the appeal by the Board.
Exhibit 10.25

 

SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

(adopted February 11, 2016)

 

The board of directors (the “Board”) of Catabasis Pharmaceuticals, Inc. (the “Company”) has approved a non-employee director compensation program to be effective at the time of the Company’s initial public offering. Under this non-employee director compensation program, the Company will pay its non-employee directors retainers in cash.  Each non-employee director will receive a cash retainer for service on the Board and for service on each committee of which the director is a member. The chairmen of the Board and of each committee will receive higher retainers for such service. The amounts of the retainers are as follows:

 

	
 
    	
 
    	
Member
   Annual
   Retainer
    	
 
    	
Chairman
   Annual
   Retainer
    	
 
    
	
Board of   Directors
    	
 
    	
$
    	
35,000
    	
 
    	
$
    	
 
    	
 
    
	
Chairman of the   Board of Directors*
    	
 
    	
35,000
    	
 
    	
 
    	
 
    
	
Audit Committee
    	
 
    	
$
    	
7,500
    	
 
    	
$
    	
20,000
    	
 
    
	
Compensation   Committee
    	
 
    	
$
    	
5,000
    	
 
    	
$
    	
10,000
    	
 
    
	
Nominating and   Corporate Governance Committee
    	
 
    	
$
    	
3,000
    	
 
    	
$
    	
7,500
    	
 
    


 




* In the event co-chairs are appointed, the retainer for Chairman of the Board of Directors will be divided equally between the co-chairs.

 

These retainers are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment shall be prorated for any portion of such quarter during which the director was not serving.  The Company will also reimburse its non-employee directors for reasonable travel and other expenses incurred in connection with attending Board and committee meetings.

 

Each director elected to the Board after the closing of the Company’s initial public offering will receive an option to purchase 13,000 shares of the Company’s common stock. Each of these options will vest as to one-third of the shares of our common stock underlying such option on each anniversary of the grant date until the third anniversary of the grant date, subject to the director’s continued service as a director, and will become exercisable in full upon a change in control of the Company.  Further, on the date of the first Board meeting held after each annual meeting of stockholders, each director that has served on the Board for at least six months will receive an option to purchase 6,500 shares of the Company’s common stock. Each of these options will vest in full on the first anniversary of the date of grant unless otherwise provided at the time of grant, subject to the director’s continued service as a director, and will become exercisable in full upon a change in control of the Company.

 

The exercise prices of the options granted under the Company’s non-employee director compensation program will equal the fair market value of the Company’s common stock on the date of grant.
CS 315822-A 05/11/2020

10 things you can do to manage 

your COVID-19 symptoms at home

Accessible Version: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html

If you have possible or confirmed COVID-19:

1. Stay home from work and 

school. And stay away from 

other public places. If you 

must go out, avoid using any 

kind of public transportation,

ridesharing, or taxis.

2. Monitor your symptoms

carefully. If your symptoms 

get worse, call your 

healthcare provider 

immediately. 

3. Get rest and stay 

hydrated. 

4. If you have a medical 

appointment, call the 

healthcare provider

ahead of time and tell 

them that you have or 

may have COVID-19.

5. For medical emergencies, 

call 911 and notify the 

dispatch personnel that 

you have or may have 

COVID-19.

6. Cover your cough and 

sneezes.

7. Wash your hands often with 

soap and water for at least 

20 seconds or clean your 

hands with an alcohol-based 

hand sanitizer that contains at 

least 60% alcohol. 

8. As much as possible, stay in a 

specific room and away from 

other people in your home. 

Also, you should use a separate 

bathroom, if available. If you 

need to be around other people 

in or outside of the home, wear 

a facemask.

9. Avoid sharing personal 

items with other people in 

your household, like dishes, 

towels, and bedding.

10. Clean all surfaces that are 

touched often, like counters, 

tabletops, and doorknobs. 

Use household cleaning 

sprays or wipes according to 

the label instructions. 

cdc.gov/coronavirus
Payment Number Payment Date Payment Amount

Payment Listing for Willowbrook Cardiovascular Associates PA

Health Diagnostic Laboratory, Inc.

23387 4/24/2012 $1,620.00

23388 4/24/2012 $2,840.00

24598 5/7/2012 $1,820.00

24599 5/7/2012 $780.00

26267 6/6/2012 $1,500.00

26268 6/6/2012 $3,260.00

28073 7/6/2012 $1,540.00

28074 7/6/2012 $4,320.00

29861 8/7/2012 $1,600.00

29862 8/7/2012 $5,180.00

31750 9/7/2012 $1,480.00

31751 9/7/2012 $5,780.00

32578 9/26/2012 $40.00

33818 10/9/2012 $1,520.00

33819 10/9/2012 $4,540.00

35764 11/6/2012 $2,100.00

35765 11/6/2012 $5,820.00

37904 12/6/2012 $1,780.00

37905 12/6/2012 $5,920.00

40115 1/7/2013 $1,680.00

40116 1/7/2013 $4,820.00

42339 2/4/2013 $1,640.00

42340 2/4/2013 $6,180.00

44288 3/6/2013 $2,120.00

44289 3/6/2013 $6,220.00

46657 4/8/2013 $1,640.00

46658 4/8/2013 $5,900.00

48870 5/7/2013 $2,100.00

48871 5/7/2013 $6,920.00

51374 6/6/2013 $2,380.00

51375 6/6/2013 $6,540.00

53696 7/5/2013 $2,020.00

Case 17-04384-KRH Doc 1-3 Filed 06/07/17 Entered 06/07/17 21:13:06 Desc

Exhibit 3 Page 1 of 2
Payment Number Payment Date Payment Amount

Payment Listing for Willowbrook Cardiovascular Associates PA

Health Diagnostic Laboratory, Inc.

53697 7/5/2013 $5,980.00

56195 8/5/2013 $1,760.00

56196 8/5/2013 $5,840.00

58756 9/5/2013 $1,900.00

58757 9/5/2013 $5,240.00

61181 10/8/2013 $2,020.00

61182 10/8/2013 $6,640.00

63677 11/5/2013 $2,640.00

63678 11/5/2013 $7,540.00

66458 12/3/2013 $2,560.00

66459 12/3/2013 $6,400.00

69250 1/7/2014 $1,620.00

69251 1/7/2014 $5,140.00

71781 2/11/2014 $1,420.00

71782 2/11/2014 $5,660.00

74123 3/6/2014 $2,020.00

74124 3/6/2014 $5,960.00

76594 4/4/2014 $1,620.00

76595 4/4/2014 $5,680.00

79638 5/5/2014 $2,120.00

79639 5/5/2014 $7,660.00

82347 6/5/2014 $2,440.00

82348 6/5/2014 $6,920.00

85006 7/14/2014 $1,920.00

85007 7/14/2014 $6,280.00

$208,580.00

Case 17-04384-KRH Doc 1-3 Filed 06/07/17 Entered 06/07/17 21:13:06 Desc

Exhibit 3 Page 2 of 2
#### UNITED STATES of America, Plaintiff-Appellee, v. Fred A. LOTFIAN, Defendant-Appellant.

No. 02-1019.

United States Court of Appeals, Fourth Circuit.

Submitted May 16, 2002.

Decided May 22, 2002.

*945Fred A. Lotfian, Appellant Pro Se. Lynne Ann Battaglia, Tamera Lynn Fine, Office of the United States Attorney, Baltimore, Maryland, for Appellee.

Before NIEMEYER, MICHAEL, and MOTZ, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

PER CURIAM.

Fred A Lotfian appeals from the district court’s order entering judgment in favor of the United States in its action to recover amounts due on a promissory note executed in connection with a student loan. We have reviewed the record and the district court’s opinion and find no reversible error. Accordingly, we affirm on the reasoning of the district court. *United States v. Lotfian,*No. CA-00-1835-PJM (D. Md. filed Dec. 7, 2001 & entered Dec. 10, 2001). We deny as moot the Government’s motion to require Lotfian to serve his informal brief. We dispense with oral argument because the facts and legal: contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED.*
§ 490.509 Data requirements. ( a ) Travel time data needed to calculate the Travel Time Reliability measures in § 490.507(a) shall come from the travel time data set, as specified in § 490.103(e). ( 1 ) State DOTs, in coordination with MPOs, shall define reporting segments in accordance with § 490.103(f). Reporting segments must be contiguous so that they cover the full extent of the mainline highways of the NHS in the State.
( 2 ) [Reserved]
( b ) State DOTs shall not replace missing travel times when data are not available in the travel time data set (data not reported, or reported as “0” or null) as specified in § 490.511(b)(1)(v).
( c ) AADT needed to calculate the Travel Time Reliability measures will be used, as reported to HPMS in June of the reporting year, to assign an annual volume to each reporting segment. Annual volume will be calculated as: Annual Volume = AADT × 365 days
( d ) The average occupancy factors for the State and/or metropolitan area (as applicable) needed to calculate Travel Time Reliability measures shall come from the most recently available data tables published by FHWA unless using other allowed data source(s).
( e ) If an NHS roadway is closed, the State DOT is not required to include those time periods for those segments of road in the calculations required for the Level of Travel Time Reliability (LOTTR) metric (see § 490.511(a)(1)).
( f ) The FHWA will post on the FHWA website, no later than August 15th of each reporting year, the CO2 factors for each on-road fuel type that will be used to calculate the GHG metric for the GHG measure in § 490.105(c)(5).
( g ) Fuel sales information needed to calculate the fuel consumed for the GHG measure in § 490.507(b) shall: ( 1 ) Represent the total number of gallons of fuel consumed by fuel type; and
( 2 ) Be based on fuels sales data for the prior calendar year, and reported to Fuels & FASH.
( h ) Annual vehicle miles traveled (VMT) needed to calculate the GHG measure in § 490.507(b) shall come from the best available data that represents the prior calendar year and is consistent, to the maximum extent practicable, with data submitted to HPMS. The VMT data needed to calculate the GHG metric in § 490.511(c) for the reference year, shall be the HPMS data as of November 30, 2023.
[82 FR 6031, Jan. 18, 2017, as amended at 83 FR 24936, May 31, 2018; 88 FR 85392, Dec. 7, 2023]
#### Northern Bank of New York v. Joseph G. Robin.

Motion granted, with ten dollars costs. Present—Ingraham, P. J., McLaughlin, Laughlin, Clarke and Scott, JJ.